CD274 and neoplasm: Besides the three antigens reported in this study, other EBV antigens expressed in EBV‐associated cancer cells may also be promising antigens, and the combination of different EBV antigens in therapeutic vaccines for various EBV‐related diseases warrants further investigation.[87] Furthermore, combining EBV therapeutic vaccines with PD‐1/PD‐L1 blocking antibodies may increase their anti‐tumor efficacy, which should be further explored.[88, 89]